Lake Street Capital Initiates Coverage on Aytu BioPharma (NASDAQ:AYTU)

Lake Street Capital started coverage on shares of Aytu BioPharma (NASDAQ:AYTU) in a research report released on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $8.00 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Ascendiant Capital Markets initiated coverage on shares of Aytu BioPharma in a research note on Monday. They issued a “buy” rating and a $12.00 price target on the stock. Wall Street Zen upgraded shares of Aytu BioPharma to a “strong-buy” rating in a research note on Friday, June 27th.

Aytu BioPharma Stock Up 3.7%

Aytu BioPharma stock opened at $2.26 on Tuesday. The company’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.51. Aytu BioPharma has a fifty-two week low of $0.95 and a fifty-two week high of $2.96. The firm has a market capitalization of $20.29 million, a price-to-earnings ratio of -3.14 and a beta of 0.13. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.03 and a quick ratio of 0.87.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 14th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.37. The firm had revenue of $18.45 million for the quarter, compared to the consensus estimate of $13.74 million. Aytu BioPharma had a net margin of 2.37% and a return on equity of 3.51%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC raised its stake in Aytu BioPharma Inc. (NASDAQ:AYTU) by 13.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 463,721 shares of the company’s stock after acquiring an additional 56,172 shares during the quarter. Stonepine Capital Management LLC owned approximately 7.52% of Aytu BioPharma worth $556,000 as of its most recent SEC filing. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.